EDAP / EDAP TMS S.A. (EDAP) CEO Marc Oczachowski on Q4 2021 Results - Earnings Call Transcript

EDAP TMS reported Q2 2023 revenues of $15.52 million, a 0.9% YoY growth that missed estimates. In Q2 2023, HIFU's total revenue growth stood at 63.6% more_horizontal

EDAP TMS S.A. is a French developer of minimally invasive medical devices for urological diseases. The company operates in three segments: High Intens more_horizontal

EDAP TMS S.A. (NASDAQ:EDAP ) Q2 2023 Earnings Conference Call August 24, 2023 8:30 AM ET Company Participants John Fraunces - Managing Director of Lif more_horizontal

- Company to host conference call and webcast on Thur sday, August 24 th at 8:30 am EDT - more_horizontal

EDAP TMS S.A. shares have pushed lower in H2 FY'23, presenting an opportunity to add on weakness. EDAP's Q1 revenues were up 13.8% YoY, with HIFU sale more_horizontal

Start Time: 08:30 January 1, 0000 9:10 AM ET EDAP TMS S.A. (NASDAQ:EDAP ) Q1 2023 Earnings Conference Call May 17, 2023, 08:30 AM ET Company Participa more_horizontal

LYON, France, March 9, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced th more_horizontal

EDAP continues to rate higher in 2023. Positive phase 2 data investigating HIFU in rectal endometriosis adds another inflection point for investors to more_horizontal